Recently Featured

Recessive Neurodevelopmental Disorder Identified Is the Most Prevalent Ever Discovered

April 4, 2026
Researchers at the Icahn School of Medicine at Mount Sinai have unveiled a previously unidentified recessive neurodevelopmental disorder (NDD) linked to the gene RNU2-2, which is projected to affect thousands in the U.S. and account for approximately 10% of known recessive NDD cases. This disorder arises from a near-total absence of U2-2 RNA, a small…

Samsung Biologics Completes Acquisition of GSK’s Manufacturing Facility

April 4, 2026
Samsung Biologics recently announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company’s first manufacturing presence in the United States. The Rockville site comprises two cGMP manufacturing plants with a combined 60,000-liter drug substance capacity, supporting both clinical and commercial biologics production across multiple manufacturing scales. With…

Non-invasive diagnostics in endometriosis: at the cusp of a turning point

April 3, 2026
Innovative non-invasive diagnostic methods for endometriosis are emerging, potentially addressing the average nine-year delay in diagnosis that many patients experience. These advancements could revolutionize the way healthcare providers identify and manage this complex condition, which affects millions of women globally. However, despite the promise of these new technologies, systemic barriers remain that could hinder their…

GDUFA IV: Fiscal Years 2028 – 2032

April 3, 2026
The FDA has initiated preparations for the fourth reauthorization of the Generic Drug User Fee Amendments (GDUFA IV), covering fiscal years 2028 to 2032. This reauthorization is crucial as it aims to enhance the efficiency of the generic drug approval process, which has significant implications for market access and competition in the pharmaceutical industry. As…

Ongoing Cases